A5066839372- SARS-CoV-2 and COVID-19 Research
- Monoclonal and Polyclonal Antibodies Research
- Hepatitis C virus research
- COVID-19 epidemiological studies
- Immunotherapy and Immune Responses
- vaccines and immunoinformatics approaches
- Bacteriophages and microbial interactions
- Ocular and Laser Science Research
- HIV Research and Treatment
- SARS-CoV-2 detection and testing
- Phytase and its Applications
- Allergic Rhinitis and Sensitization
- Platelet Disorders and Treatments
- T-cell and B-cell Immunology
- Animal Virus Infections Studies
- Blood Coagulation and Thrombosis Mechanisms
- Nuts composition and effects
- Safety Warnings and Signage
- Complement system in diseases
- Remote Sensing and LiDAR Applications
- Infrared Target Detection Methodologies
- COVID-19 Clinical Research Studies
- Botanical Research and Chemistry
- Vaccine Coverage and Hesitancy
- Animal Diversity and Health Studies
Amsterdam University Medical Centers
2019-2023
University of Amsterdam
2019-2023
Amsterdam University of Applied Sciences
2022
Amsterdam UMC Location University of Amsterdam
2022
Sanquin
2018-2019
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is continuing to disrupt personal lives, global healthcare systems, and economies. Hence, there an urgent need for a vaccine that prevents viral infection, transmission, disease. Here, we present two-component protein-based nanoparticle displays multiple copies of the SARS-CoV-2 spike protein. Immunization studies show this induces potent neutralizing antibody responses in mice, rabbits, cynomolgus macaques....
Delineating the origins and properties of antibodies elicited by SARS-CoV-2 infection vaccination is critical for understanding their benefits potential shortcomings. Therefore, we investigate spike (S)-reactive B cell repertoire in unexposed individuals flow cytometry single-cell sequencing. We show that ∼82% S-reactive cells harbor a naive phenotype, which represents an unusually high fraction total human (∼0.1%). Approximately 10% these share IGHV1-69/IGKV3-11 receptor pairing, enrichment...
Abstract The HIV-1 envelope glycoprotein trimer is poorly immunogenic because it covered by a dense glycan shield. As result, recombinant Env glycoproteins generally elicit inadequate antibody levels that neutralize clinically relevant, neutralization-resistant (Tier-2) strains. Multivalent antigen presentation on nanoparticles an established strategy to increase vaccine-driven immune responses. However, due nanoparticle instability in vivo, the display of non-native structures, and...
Hepatitis C virus (HCV) infection affects approximately 58 million people and causes ~300,000 deaths yearly. The only target for HCV neutralizing antibodies is the highly sequence diverse E1E2 glycoprotein. Eliciting broadly that recognize conserved cross-neutralizing epitopes important an effective vaccine. However, most recombinant glycoprotein vaccines, which usually include E2, induce weak antibody responses. Here, we describe soluble immunogens were generated by permutation of E1 E2...
Mutations in the gene encoding for complement regulator factor H (FH) severely disrupt its normal function to protect human cells from unwanted activation, resulting diseases such as atypical hemolytic uremic syndrome (aHUS). aHUS presents with severe anemia, thrombocytopenia, and renal disease, leading end-stage failure. Treatment of complement-mediated aHUS, by inhibiting terminal pathway, has proven be successful but at same time fails preserve protective role against pathogens. To...
An effective preventive vaccine for hepatitis C virus (HCV) remains a major unmet need. Antigenic region 3 (AR3) on the E1E2 envelope glycoprotein complex overlaps with CD81 receptor binding site and represents an important epitope broadly neutralizing antibodies (bNAbs) is therefore HCV design. Most AR3 bNAbs utilize VH1-69 gene share structural features that define AR3C-class of bNAbs. In this work, we identify recombinant glycoproteins based permuted E2E1 trimer design bind to inferred...
Summary The SARS-CoV-2 pandemic is continuing to disrupt personal lives, global healthcare systems and economies. Hence, there an urgent need for a vaccine that prevents viral infection, transmission disease. Here, we present two-component protein-based nanoparticle displays multiple copies of the spike protein. Immunization studies show this induces potent neutralizing antibody responses in mice, rabbits cynomolgus macaques. vaccine-induced immunity protected macaques against high dose...
The SARS-CoV-2 pandemic is continuing to disrupt personal lives, global healthcare systems and economies. Hence, there an urgent need for a vaccine that prevents viral infection, transmission disease. Here, we present two-component protein-based nanoparticle displays multiple copies of the spike protein. Immunization studies show this induces potent neutralizing antibody responses in mice, rabbits cynomolgus macaques. vaccine-induced immunity protected macaques against high dose challenge,...
Abstract Delineating the origins and properties of antibodies elicited by SARS-CoV-2 infection vaccination is critical for understanding their benefits potential shortcomings. Therefore, we investigated spike (S)-reactive B cell repertoire in unexposed individuals flow cytometry single-cell sequencing. We found that ∼82% S-reactive cells show a naive phenotype, which represents an unusually high fraction total human (∼0.1%). Approximately 10% these shared IGHV1-69/IGKV3-11 receptor pairing,...
Abstract An effective preventive vaccine for hepatitis C virus (HCV) remains a major unmet need. Antigenic region 3 (AR3) on the E1E2 envelope glycoprotein complex overlaps with CD81 receptor binding site and represents an important epitope design aimed at inducing broadly neutralizing antibodies (bNAbs). Most AR3 bNAbs utilize V H 1-69 gene share structural features that define AR3C-class of HCV bNAbs. In this work, we identified trimers bind to inferred germline precursors bNAbs, providing...
Abstract The HIV-1 envelope glycoprotein trimer is poorly immunogenic because it covered by a dense glycan shield. As result, recombinant Env glycoproteins generally elicit inadequate antibody levels that neutralize clinically-relevant, neutralization-resistant (Tier-2) strains. Multivalent antigen presentation on nanoparticles an established strategy to increase vaccine-driven immune responses. However, due nanoparticle instability in vivo, the display of non-native structures, and...